Helen K. Chew, M.D.
- Director, Clinical Breast Cancer Program
- Director, Hematology and Oncology Fellowship Program
Helen K. Chew is the leader of the UC Davis Cancer Center clinical breast cancer program. She is responsible for coordinating surgical, medical and radiation oncology services and clinical trials for breast cancer.
Dr. Chew's research interests involve novel treatments for breast cancer, serum tumor markers, complications of, cancer, including thromboembolism, and treatment-related cognitive dysfunction.
Hematology and Oncology
M.D., University of Texas Health Sciences Center, San Antonio TX 1991
B.S., Stanford University, Stanford CA 1986
Internship: Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994
Internal Medicine, University of Texas Health Sciences Center, San Antonio TX 1991-1994
Hematology/Oncology, University of Texas Health Sciences Center, San Antonio TX, 1995-1998
Molecular Medicine, University of Texas Health Sciences Center, San Antonio TX, 1996-2000
American Board of Internal Medicine,
American Board of Internal Medicine, Medical Oncology,
CA Medical Board, License,
Texas Medical Board,
American Society of Clinical Oncology
Fellow, American College of Physicians
Southwest Oncology Group
Honors and Awards
UC Davis Health System Faculty Recognition Certificate of Excellence and Achievement Award, 2007, 2008
Find a Cure Award, South Placer Breast Cancer Endowment, 2007
Joyce Raley Teel Award for outstanding dedication to the cause of breast cancer, 2006
Christine & Helen Landgraf Memorial Award, 2001
VA Career Development Award, 1998
Chief Resident, Department of Internal Medicine, 1994, 1995
Select Recent Publications
For a comprehensive list of Dr. Chew's publications, please click here (opens new window).
Ho C, Davies AM, Sangha RS, Lau D, Lara P, Chew HK, Beckett L, Mack PC, Riess JW, Gandara DR. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer. Invest New Drugs. 2013 Dec;31(6):1587-91. doi:10.1007/s10637-013-0024-y.
Schott AF, Barlow WE, Albain KS, Chew HK, Wade JL, Lanier KS, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist. 2012;17(2):179-87. doi:10.1634/theoncologist.2011-0235.
Barnhard S, Pai A, Chew HK, Song JY. Richter's syndrome with aberrant CD2 and CD4 expression. J Clin Oncol. 2012 Sep 10;30(26):e243-5. doi:10.1200/JCO.2011.40.2065.
Chew HK, Somlo G, Mack PC, Gitlitz B, Gandour-Edwards R, Christensen S, Linden H, Solis LJ, Yang X, Davies AM. Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors. Ann Oncol. 2012 Apr;23(4):1023-9. doi:10.1093/annonc/mdr328.
Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A, Albain KS. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010 Apr 1;28(10):1671-6. doi:10.1200/JCO.2008.20.2119.
Sandhu R, Pan CX, Wun T, Harvey D, Zhou H, White RH, Chew HK. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer. 2010 Jun 1;116(11):2596-603. doi:10.1002/cncr.25004.
de Leoz ML, Young LJ, An HJ, Kronewitter SR, Kim J, Miyamoto S, Borowsky AD, Chew HK, Lebrilla CB. High-Mannose Glycans are Elevated during Breast Cancer Progression. Mol Cell Proteomics. 2010 Jan;10(1):M110.002717. doi:10.1074/mcp.M110.002717.
Ku G, Chew HK, Harvey DJ, Zhou H, White RH, Wun T. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and mortality. Blood. 2009 Apr 23;113(17):3911-3917. doi:10.1182/blood-2008-08-175745.
Barkauskas DA, An HJ, Kronewritter SR, deLeoz ML, Chew HK, de Vere-White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics. 2009 Jan 15;25(2):251-257. doi:10.1093/bioinformatics/btn610.
Chew HK, Doroshow J, Frankel P, Margolin K, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff P, Gandara DR, Albain K. Phase II Studies of Gemcitabine and Cisplatin in Heavily and Minimally Pretreated Metastatic Breast Cancer. J Clin Oncol. 2009 May 1;27(13):2163-2169. doi:10.1200/JCO.2008.17.4839.